Tesamorelin: The Growth Hormone Peptide That Actually Has FDA Approval

# Tesamorelin: The Growth Hormone Peptide That Actually Has FDA Approval

In a space full of peptides with limited clinical data, tesamorelin stands out: it's the only growth hormone-releasing hormone (GHRH) analog with FDA approval. While most peptides in the longevity and performance space are prescribed off-label based on animal studies and small trials, tesamorelin has robust clinical evidence behind it.

Here's what it does and whether it belongs in your protocol.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of GHRH — growth hormone-releasing hormone, the signal your hypothalamus naturally sends to stimulate pituitary growth hormone secretion. Unlike synthetic growth hormone itself (which directly administers GH), tesamorelin works through your body's own regulatory axis: it tells the pituitary to produce and release more growth hormone naturally.

FDA approval: Egrifta (tesamorelin) was approved in 2010 for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. This is its only approved indication, but its mechanism has significant implications for broader metabolic and body composition applications.

How It Compares to Other GH Peptides

The GH peptide landscape includes several agents:

GHRH analogs (stimulate GHRH receptors): - Tesamorelin — FDA-approved, most studied, 40-amino acid sequence modified for stability - CJC-1295 — longer-acting GHRH analog, widely used off-label - Sermorelin — shorter, first-generation GHRH analog

GHRPs (growth hormone releasing peptides, work at ghrelin receptors): - Ipamorelin — cleanest GHRP, highly specific, minimal cortisol/prolactin elevation - Hexarelin, GHRP-6 — effective but dirtier side effect profiles

Combination stacks: CJC-1295 + ipamorelin or tesamorelin + ipamorelin work synergistically — GHRH analogs and GHRPs act at different receptors and amplify each other's effect.

Tesamorelin's advantage over CJC-1295: better clinical documentation, predictable pharmacokinetics, and the confidence of FDA scrutiny. Its disadvantage: higher cost, shorter half-life requiring daily injection.

What Tesamorelin Actually Does

Visceral fat reduction is the most documented effect. In HIV lipodystrophy trials, tesamorelin reduced trunk fat by approximately 15–20% while having minimal effect on peripheral fat or lean mass — an unusually selective body composition benefit.

Outside of HIV patients, the same mechanism applies: elevated GH and IGF-1 drive preferential reduction of visceral adiposity while supporting lean mass preservation. This makes tesamorelin particularly interesting for metabolic health and body composition optimization.

Lean mass: GH is anabolic. Tesamorelin-driven GH pulses support muscle protein synthesis and can improve body composition even without weight change — replacing fat with lean tissue.

Recovery and connective tissue: Like all GH-axis peptides, tesamorelin supports collagen synthesis and soft tissue repair. Some patients and physicians use it specifically for this in the context of joint health and injury recovery.

Lipid profile: Tesamorelin has shown improvements in triglycerides and LDL in some clinical data — a cardiovascular benefit beyond body composition.

Cognitive function: Emerging research suggests GH/IGF-1 signaling plays a role in cognitive function and neuroprotection. Tesamorelin is being studied in Alzheimer's and mild cognitive impairment — preliminary results are promising, though far from conclusive.

Dosing Protocol

Standard dosing in approved indication: 2 mg subcutaneously daily. Off-label protocols commonly use: - 1–2 mg daily, typically injected subcutaneously in the abdomen - Cycling: Some physicians recommend 5 days on, 2 days off to maintain receptor sensitivity - Often combined with ipamorelin (100–200 mcg) at bedtime for synergistic GH pulse amplification

Timing: 30–60 minutes before sleep or training. GH secretion follows a circadian rhythm with the largest natural pulse occurring during early deep sleep — aligning peptide administration with this pulse amplifies the effect.

Side Effects and Considerations

Fluid retention — Elevated GH/IGF-1 causes water retention, particularly in the first few weeks. This typically resolves and is dose-dependent.

Joint discomfort — Some patients experience carpal tunnel-like symptoms (tingling, numbness in hands) related to fluid retention. Usually resolves with dose reduction.

Blood glucose effects — GH is counter-regulatory to insulin. Monitor glucose, especially if you have metabolic risk factors. Tesamorelin's effect on glucose is generally modest at therapeutic doses.

IGF-1 elevation — Chronically supraphysiologic IGF-1 raises theoretical cancer concerns (IGF-1 is growth-promoting). Clinical tesamorelin data doesn't demonstrate increased cancer risk, but monitoring IGF-1 levels is prudent.

Not for: Active malignancy, pituitary tumor, hypopituitarism from pituitary tumor or radiation, pregnancy.

Monitoring on Tesamorelin

Your physician should monitor: - IGF-1: Baseline and periodically. Target upper-normal range (not supraphysiologic). - Fasting glucose / HbA1c: Especially in pre-diabetic patients. - Lipid panel: To assess metabolic benefit over time. - Body composition: DEXA scan if available — the most objective way to track visceral fat and lean mass changes.

Who Is Tesamorelin For?

Best candidates: - Men 35+ experiencing age-related GH decline (common from mid-30s onward) - Patients with elevated visceral adiposity (the metabolically dangerous "belly fat") - Athletes or active individuals focused on body composition optimization - Patients interested in longevity protocols targeting metabolic health - Those already familiar with other peptides seeking the most evidence-based GH option

Less appropriate: - Patients with active cancer or significant cardiovascular disease - Those unwilling to do daily subcutaneous injections - Anyone not open to regular lab monitoring

Tesamorelin isn't the most exciting peptide in terms of anecdotal reports — it doesn't produce the dramatic recovery stories of BPC-157 or the deep sleep effects of MK-677. But if you want the GH peptide with the best clinical data and regulatory backing, it's the clear choice.

Marrow's physicians can evaluate whether tesamorelin fits your protocol and monitor your response appropriately.